Charles L Shapiro, MD
- PROFESSOR | Medicine, Hematology and Medical Oncology
Specialties:Cancer (Oncology), Hematology-Oncology
Dr. Shapiro is Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He is the Director of the Translational Breast Cancer Research for the Mount Sinai Health System and Director of Survivorship Programs at The Tisch Cancer Institute. Dr. Shapiro sees patients at the Dubin Breast Center of The Tisch Cancer Institute.
Dr. Shapiro’s clinical research interests include bone health, specifically the impact of adjuvant chemotherapy on bone loss in premenopausal women; development of new, effective treatments; and clinical trials that feature novel therapies. Dr. Shapiro is committed to providing the best treatments tailored to each patient for optimal outcomes and empowering women to regain control over their lives.
Professor of Medicine
Director of Translational Breast Cancer Research
Director of Cancer Survivorship, Tisch Cancer Institute
Division of Hematology/Medical Oncology Department of Medicine
MD, S.U.N.Y, Buffalo - School of Med & Biomed Sciences
Internship, Internal Medicine, Temple University Hospital
Residency, Internal Medicine, Temple University Hospital
Fellowship, Medical Oncology, Beth Israel Deaconess Medical Center- Harvard Medical School
Physicians recognized for being in the top 10 percent for patient satisfaction, nationally
America's Top Doctors for Cancer
Bertha Bouroncle Teaching Award
America's Top Doctors
Best Doctors in America
American Cancer Society Clinical Oncology Career Development
The James Champion Award
Bacilli Award for Academic Excellence
John Watson Award for Scholarship in Medicine
Alpha Omega Alpha
The focus of my research is investigator-initiated early phase clinical trials in breast cancer. Areas of interest include: breast cancer survivorship, in particular the impact and treatment of adjuvant chemotherapy-induced bone loss in premenopausal women; microRNA profiling of triple negative breast cancers to define subsets that have better or worse prognosis; and preclinical evaluations of novel drugs in collaboration with a medicinal chemist, including a PDK-1 inhibitor, AMP kinase inhibitor and the PARP inhibitors. At Mount Sinai I plan to form collaborations with laboratory-based scientists to evaluate novel drugs preclinically, develop investigator-initiated trials to further define subsets of triple negative breast cancers using genomic methods, and to conduct investigator-initiated trials in breast cancer survivorship.